Safety and Tolerability of Low-Dose Full-Spectrum Cannabidiol in Long-Term Virally Suppressed Adults with HIV: A Randomized Double-Blind Placebo-Controlled Trial

In a 12-week randomized double-blind placebo-controlled trial involving 80 virally suppressed adults with HIV, low-dose full-spectrum cannabidiol was found to be well-tolerated with no clinically meaningful adverse effects on liver, kidney, or HIV-specific parameters, though exploratory analyses suggested a reduction in total bilirubin and heart rate in men.

The Gist

The Big Picture: A "Tune-Up" for Long-Term HIV Survivors

Imagine living with HIV is like driving a car that has been running for a very long time. Thanks to modern medicine (antiretroviral therapy), the engine is running perfectly, and the car isn't breaking down. The virus is "suppressed"—it's hiding in the garage, not on the road.

However, even when the car is running smoothly, the engine still hums with a low-level vibration. In people with HIV, this is called chronic inflammation. It's like the car's engine is always slightly overheating, which can wear down the parts (heart, kidneys, liver) over time, leading to early aging and other health issues.

Scientists wondered: Could a natural "coolant" help? Specifically, they wanted to test Cannabidiol (CBD), a non-psychoactive compound from the cannabis plant. They didn't want to test the "high" part (THC), just the calming, anti-inflammatory part (CBD).

The Experiment: The "Oil Change" Test

The researchers set up a strict, double-blind experiment (like a secret recipe contest where neither the chefs nor the judges know who made which dish).

• The Participants: 80 adults who had successfully controlled their HIV for a long time (about 14 years on average).
• The Treatment: They were split into two groups.
  • Group A: Took a specific dose of full-spectrum CBD oil (1 mg per kilogram of body weight, twice a day). Think of this as a high-quality, standardized "oil change" for the body's internal systems.
  • Group B: Took a placebo (just plain MCT oil, like a neutral carrier fluid with no active ingredients).
• The Duration: They did this for 12 weeks, followed by a 4-week observation period.
• The Goal: The main question wasn't "Does it cure HIV?" (it doesn't). The question was: "Is it safe?" They wanted to make sure this "oil" didn't clog the engine or damage the transmission.

What They Checked (The Dashboard)

Just like a mechanic checks a car's dashboard, the doctors ran extensive tests on the participants' bodies:

1. The Liver (The Filter): Did the CBD cause the liver to get stressed? (Checked via blood enzymes).
2. The Kidneys (The Waste Disposal): Did the kidneys struggle to filter blood? (Checked via creatinine levels).
3. The Heart (The Engine RPM): Did the heart rate or blood pressure get weird?
4. The Virus (The Intruder): Did the hidden virus wake up? (Checked via viral load and DNA).

The Results: A Smooth Ride

1. The Safety Verdict: Green Light 🟢
The most important finding is that the CBD was very safe.

• The liver and kidneys didn't show any signs of damage.
• The virus stayed suppressed; the "intruder" didn't wake up.
• No one got sick because of the oil. It was well-tolerated by almost everyone.

2. The Surprising Side Effects (The "Ghost" Signals)
While the main goal was safety, the researchers noticed two interesting, though small, changes that need more study:

• The Liver's "Clean-Up": In the group taking CBD, a specific marker in the blood called bilirubin went down slightly. Imagine bilirubin as a bit of "rust" in the blood. The CBD group seemed to have slightly less rust than the placebo group. This is exciting but needs more proof.
• The Heart's "Cruise Control": This is the most interesting finding. In men specifically, the heart rate slowed down slightly while on the CBD.
  • Analogy: Imagine a runner who is jogging at a steady 75 steps per minute. When they took the CBD, their pace naturally slowed to a relaxed 64 steps per minute. They weren't tired; they were just more relaxed.
  • Note: This happened in men, but not in women. It's like the CBD acted as a "cruise control" for men's hearts, but the women's hearts didn't react the same way.

The Takeaway: What Does This Mean?

Think of this study as a test drive for a new car part.

• Did it break the car? No. It was safe.
• Did it fix the engine? We don't know yet. The study wasn't designed to prove it cures inflammation, only that it didn't cause harm.
• Did it do anything cool? Maybe. It seemed to calm the heart down in men and clean up a tiny bit of "rust" in the blood.

The Bottom Line:
For people living with HIV who have their virus under control, taking a low dose of this specific, high-quality CBD oil for three months appears to be safe. It didn't hurt their liver, kidneys, or heart, and it didn't wake up the virus.

The researchers are now saying, "We've cleared the safety hurdles. Now, let's build a bigger, longer test to see if this 'coolant' actually helps reduce that chronic inflammation and if the heart-rate effect is real and useful."

Important Note: This was a preprint (a draft before final peer review), so while the data looks promising, doctors shouldn't prescribe this yet based solely on this paper. It's a "wait and see" situation until more studies confirm these findings.

Technical Summary

1. Problem Statement

Despite the success of antiretroviral therapy (ART) in suppressing HIV viral loads, people living with HIV (PWH) often suffer from chronic inflammation and immunosenescence ("inflammaging"), leading to early-onset comorbidities such as cardiovascular and kidney diseases. While cannabis-based medicines (CBM) have shown potential anti-inflammatory properties, data regarding their safety and tolerability in the specific context of long-term HIV infection is scarce. Existing studies often rely on recreational cannabis use (uncontrolled THC/CBD ratios) or small, open-label pilot studies. There is a critical need for rigorous, randomized controlled trials (RCTs) to evaluate the safety of standardized, pharmaceutical-grade, full-spectrum cannabidiol (CBD) in PWH, particularly regarding renal, hepatic, cardiac, and immunovirologic parameters.

2. Methodology

• Study Design: A double-blind, randomized, placebo-controlled trial (RCT) conducted at the University Hospital of Orléans, France.
• Participants: 80 adults with HIV who had been virally suppressed (<50 copies/mL) for at least 3 years (median duration of suppression: 14 years). The cohort included 30% women (n=25), with a median age of 54 years.
• Intervention:
  • CBD Group: Received full-spectrum CBD oil (CBD50 LGP CLASSIC, Little Green Pharma) containing <0.3% THC, formulated in MCT oil. Dosage was weight-based: 1 mg/kg twice daily.
  • Placebo Group: Received MCT oil only.
  • Duration: 12 weeks of treatment followed by a 4-week follow-up (total 16 weeks).
• Primary vs. Secondary Objectives: The primary endpoint (autophagy gene expression) is described in a separate manuscript. This paper focuses on the secondary objective: clinical and biological safety and tolerability.
• Assessments:
  • Hemodynamic: Heart rate and ECG monitored at Weeks 0, 4, 12, and 16.
  • Hepatic: ALT, AST, total and conjugated bilirubin (W0, W4, W8, W12).
  • Renal: Creatinine and estimated creatinine clearance (W0, W4, W12).
  • Immunovirologic: CD4/CD8 counts, plasma viral load, and cell-associated HIV-1 DNA.
• Statistical Analysis: Mixed-effects models were used to assess longitudinal changes, adjusted for baseline age, sex, BMI, CD4 count, and duration of viral suppression. Exploratory subgroup analyses were performed by sex.

3. Key Contributions

• First RCT of its Kind: This is the first randomized, placebo-controlled trial assessing the safety of a pharmaceutical-grade, full-spectrum CBD oil specifically in a cohort of long-term virally suppressed PWH.
• Standardization: Unlike previous studies using variable recreational products, this trial utilized a GMP-certified, standardized product with a fixed, weight-based dosing regimen.
• Inclusion of Women: The study achieved a 30% female enrollment rate, addressing a common gap in HIV clinical trials where women are historically underrepresented, allowing for sex-stratified safety analysis.
• Comprehensive Safety Profile: The study provides a rigorous assessment of renal, hepatic, cardiac, and immunovirologic safety over a 12-week period, filling a gap in the literature regarding long-term CBD use in HIV.

4. Key Results

• Tolerability & Adverse Events: The treatment was well-tolerated. No clinically meaningful differences in adverse events were observed between the CBD and placebo groups.
• Renal Safety: No significant changes were observed in serum creatinine or creatinine clearance in either group. CBD administration did not alter renal function.
• Hepatic Safety:
  • Aminotransferases (ALT, AST) and conjugated bilirubin remained stable with no significant differences between groups.
  • Total Bilirubin: A statistically significant reduction in total bilirubin was observed in the CBD arm compared to placebo at Week 12 (p=0.046 in adjusted models). This effect was more pronounced in males.
• Cardiac Safety:
  • Blood pressure and ECG parameters showed no clinically significant differences between groups.
  • Heart Rate: In the overall population, the CBD group had a lower heart rate at Week 12 (67 vs. 73 bpm) and Week 16 (68 vs. 75 bpm).
  • Sex-Stratified Analysis: The heart rate reduction was significant only in men. At Week 12, men in the CBD group had a median heart rate of 64 bpm vs. 73 bpm in placebo (p=0.043); at Week 16, 63 bpm vs. 78 bpm (p=0.019). No significant change was observed in women.
• Immunovirologic Safety:
  • Plasma viral load remained undetectable in both arms.
  • HIV-1 DNA levels (viral reservoir) and CD4/CD8 ratios remained stable.
  • No evidence of immunovirologic harm or interference with ART efficacy.

5. Significance and Conclusion

• Safety Confirmation: The study concludes that low-dose (1 mg/kg BID), full-spectrum, pharmaceutical-grade CBD is safe and well-tolerated for 12 weeks in adults with long-term suppressed HIV. It does not compromise renal, hepatic, or cardiac function, nor does it negatively impact HIV viral control.
• Exploratory Findings: The observed reductions in total bilirubin and resting heart rate (specifically in men) are considered exploratory. The authors suggest these may be related to anti-inflammatory effects or autonomic modulation but emphasize the need for larger, adequately powered trials to confirm these signals and investigate underlying mechanisms (e.g., pharmacokinetics, inflammatory biomarkers).
• Clinical Implications: These findings support the potential use of standardized CBD as an adjunct therapy for PWH to manage inflammation without compromising HIV treatment outcomes. However, the authors recommend prudent liver-function monitoring, particularly at higher doses or in patients with pre-existing hepatic conditions.
• Future Directions: The study highlights the necessity for future trials to include pharmacokinetic data, inflammatory panels, and heart-rate variability measures to fully understand the mechanistic pathways and sex-specific responses to CBD in the HIV population.